457 related articles for article (PubMed ID: 22580498)
1. Role of DLC1 tumor suppressor gene and MYC oncogene in pathogenesis of human hepatocellular carcinoma: potential prospects for combined targeted therapeutics (review).
Zimonjic DB; Popescu NC
Int J Oncol; 2012 Aug; 41(2):393-406. PubMed ID: 22580498
[TBL] [Abstract][Full Text] [Related]
2. Integrative genomic identification of genes on 8p associated with hepatocellular carcinoma progression and patient survival.
Roessler S; Long EL; Budhu A; Chen Y; Zhao X; Ji J; Walker R; Jia HL; Ye QH; Qin LX; Tang ZY; He P; Hunter KW; Thorgeirsson SS; Meltzer PS; Wang XW
Gastroenterology; 2012 Apr; 142(4):957-966.e12. PubMed ID: 22202459
[TBL] [Abstract][Full Text] [Related]
3. DLC1: a significant GAP in the cancer genome.
Lahoz A; Hall A
Genes Dev; 2008 Jul; 22(13):1724-30. PubMed ID: 18593873
[TBL] [Abstract][Full Text] [Related]
4. The tumor suppressor DLC1 inhibits cancer progression and oncogenic autophagy in hepatocellular carcinoma.
Wu HT; Xie CR; Lv J; Qi HQ; Wang F; Zhang S; Fang QL; Wang FQ; Lu YY; Yin ZY
Lab Invest; 2018 Aug; 98(8):1014-1024. PubMed ID: 29785050
[TBL] [Abstract][Full Text] [Related]
5. DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma.
Xue W; Krasnitz A; Lucito R; Sordella R; Vanaelst L; Cordon-Cardo C; Singer S; Kuehnel F; Wigler M; Powers S; Zender L; Lowe SW
Genes Dev; 2008 Jun; 22(11):1439-44. PubMed ID: 18519636
[TBL] [Abstract][Full Text] [Related]
6. Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with growth suppressor function and is underexpressed in hepatocellular carcinoma.
Ching YP; Wong CM; Chan SF; Leung TH; Ng DC; Jin DY; Ng IO
J Biol Chem; 2003 Mar; 278(12):10824-30. PubMed ID: 12531887
[TBL] [Abstract][Full Text] [Related]
7. Genetic alterations in hepatocellular carcinoma: An update.
Niu ZS; Niu XJ; Wang WH
World J Gastroenterol; 2016 Nov; 22(41):9069-9095. PubMed ID: 27895396
[TBL] [Abstract][Full Text] [Related]
8. Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias.
Zondervan PE; Wink J; Alers JC; IJzermans JN; Schalm SW; de Man RA; van Dekken H
J Pathol; 2000 Oct; 192(2):207-15. PubMed ID: 11004697
[TBL] [Abstract][Full Text] [Related]
9. Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and Jab1 as a potential target for 8q gain in hepatocellular carcinoma.
Patil MA; Gütgemann I; Zhang J; Ho C; Cheung ST; Ginzinger D; Li R; Dykema KJ; So S; Fan ST; Kakar S; Furge KA; Büttner R; Chen X
Carcinogenesis; 2005 Dec; 26(12):2050-7. PubMed ID: 16000397
[TBL] [Abstract][Full Text] [Related]
10. NOXIN as a cofactor of DNA polymerase-primase complex could promote hepatocellular carcinoma.
Zhang ZZ; Huang J; Wang YP; Cai B; Han ZG
Int J Cancer; 2015 Aug; 137(4):765-75. PubMed ID: 25612832
[TBL] [Abstract][Full Text] [Related]
11. Significance of genetic variants in DLC1 and their association with hepatocellular carcinoma.
Xie CR; Sun HG; Sun Y; Zhao WX; Zhang S; Wang XM; Yin ZY
Mol Med Rep; 2015 Sep; 12(3):4203-4209. PubMed ID: 26095787
[TBL] [Abstract][Full Text] [Related]
12. Aberrant DNA Methylation Patterns of Deleted in Liver Cancer 1 Isoforms in Hepatocellular Carcinoma.
Pan J; Li D; Fan X; Cheng J; Jin S; Chen P; Lin H; Li Y
DNA Cell Biol; 2023 Mar; 42(3):140-150. PubMed ID: 36917700
[TBL] [Abstract][Full Text] [Related]
13. Deleted in liver cancer 1 isoforms are distinctly expressed in human tissues, functionally different and under differential transcriptional regulation in hepatocellular carcinoma.
Ko FC; Yeung YS; Wong CM; Chan LK; Poon RT; Ng IO; Yam JW
Liver Int; 2010 Jan; 30(1):139-48. PubMed ID: 19874489
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of deleted in liver cancer 1 gene on gallbladder cancer growth through induction of cell cycle arrest and apoptosis.
Qin Y; Chu B; Gong W; Wang J; Tang Z; Shen J; Quan Z
J Gastroenterol Hepatol; 2014 May; 29(5):964-72. PubMed ID: 24329682
[TBL] [Abstract][Full Text] [Related]
15. DLC1 suppresses distant dissemination of human hepatocellular carcinoma cells in nude mice through reduction of RhoA GTPase activity, actin cytoskeletal disruption and down-regulation of genes involved in metastasis.
Zhou X; Zimonjic DB; Park SW; Yang XY; Durkin ME; Popescu NC
Int J Oncol; 2008 Jun; 32(6):1285-91. PubMed ID: 18497990
[TBL] [Abstract][Full Text] [Related]
16. Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma.
Wong CM; Yam JW; Ching YP; Yau TO; Leung TH; Jin DY; Ng IO
Cancer Res; 2005 Oct; 65(19):8861-8. PubMed ID: 16204057
[TBL] [Abstract][Full Text] [Related]
17. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
18. Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression.
Yam JW; Ko FC; Chan CY; Jin DY; Ng IO
Cancer Res; 2006 Sep; 66(17):8367-72. PubMed ID: 16951145
[TBL] [Abstract][Full Text] [Related]
19. A tumor suppressor enhancing module orchestrated by GATA4 denotes a therapeutic opportunity for GATA4 deficient HCC patients.
Lu F; Zhou Q; Liu L; Zeng G; Ci W; Liu W; Zhang G; Zhang Z; Wang P; Zhang A; Gao Y; Yu L; He Q; Chen L
Theranostics; 2020; 10(2):484-497. PubMed ID: 31903133
[No Abstract] [Full Text] [Related]
20. Recurrent and nonrandom DNA copy number and chromosome alterations in Myc transgenic mouse model for hepatocellular carcinogenesis: implications for human disease.
Zimonjic DB; Ullmannova-Benson V; Factor VM; Thorgeirsson SS; Popescu NC
Cancer Genet Cytogenet; 2009 May; 191(1):17-26. PubMed ID: 19389504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
